Potassium%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an electrolyte replacement used to treat and prevent hypokalemia. It is available in oral and intravenous (IV) formulations. ## Primary Indications * Treatment and prevention of hypokalemia. * Potassium-containing intravenous fluid replacement. ## Adult Dosing **Oral:** * **Prevention of hypokalemia:** Typically 20 mEq (10-15 mmol) per day, divided into 1-2 doses. * **Treatment of hypokalemia:** 40-100 mEq (20-50 mmol) per day, divided into 2-4 doses. Maximum recommended daily intake is generally 200 mEq (100 mmol). * **Maximum single oral dose:** 20 mEq (10 mmol) should be administered at one time, especially in patients with renal impairment, to minimize risk of GI irritation and hyperkalemia. * **Preparation:** Always dilute oral liquid preparations in at least 4 ounces of water or juice. **Intravenous (IV):** * **Prevention of hypokalemia:** 10-20 mEq (5-10 mmol) per hour, added to a large volume infusate (e.g., 1L of D5W or NS). * **Treatment of hypokalemia:** 20-40 mEq (10-20 mmol) per hour, added to a large volume infusate. * **Maximum IV infusion rate:** Generally not to exceed 10-20 mEq/hour, and should not exceed 40 mEq/hour in critical care settings with continuous ECG monitoring. Higher rates may be used in life-threatening hypokalemia but require continuous ECG monitoring and central venous access. * **Maximum concentration for peripheral IV:** Generally limited to 40 mEq/L to avoid phlebitis. * **Maximum concentration for central IV:** Up to 80-100 mEq/L may be used in critical situations, but rates exceeding 10 mEq/hour still require careful consideration and monitoring. * **Maximum single IV dose:** Not applicable; dosing is based on rate and total daily needs. *Note: Specific dosing regimens and maximums can vary based on local protocols, patient clinical status, and severity of hypokalemia.* ## Pediatric Dosing * **General Dosing:** Dosing is highly individualized based on age, weight, serum potassium levels, and clinical condition. * **Maintenance:** Typically 1-2 mEq/kg/day, not to exceed adult maximums. * **Treatment of hypokalemia:** May range from 2-4 mEq/kg/day, divided into multiple doses. * **IV infusion rates:** Typically limited to 0.5-1 mEq/kg/hour, not to exceed 10-20 mEq/hour (whichever is lower) depending on patient status and monitoring. * **Maximum concentration for peripheral IV:** Usually 40 mEq/L. * **Maximum concentration for central IV:** May be higher, but requires careful assessment. *Note: Pediatric potassium replacement requires careful calculation and frequent monitoring.* ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Patients with impaired renal function are at increased risk of hyperkalemia. Closely monitor serum potassium. In severe renal impairment, potassium supplementation may be contraindicated. ## Contraindications * Hyperkalemia. * Conditions that may predispose to hyperkalemia, such as chronic renal failure, untreated Addison's disease, acute dehydration, extensive tissue breakdown (e.g., severe burns, aplastic anemia), or the administration of potassium-sparing diuretics. * Certain gastrointestinal obstructions or delayed gastric emptying. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal discomfort. * **Serious:** Hyperkalemia (manifesting as muscle weakness, fatigue, paresthesias, arrhythmias, cardiac arrest), gastrointestinal ulceration, bleeding, perforation (especially with rapid release oral formulations or undiluted IV administration). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride, triamterene):** Increased risk of hyperkalemia. * **ACE inhibitors and ARBs:** Increased risk of hyperkalemia. * **NSAIDs:** May impair potassium excretion, increasing risk of hyperkalemia. * **Beta-blockers:** May impair potassium distribution into cells, increasing serum potassium. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can decrease it. * **Sodium polystyrene sulfonate:** Used to treat hyperkalemia; concurrent administration is generally avoided unless for specific reasons under close monitoring. ## Monitoring * **Serum potassium levels:** Frequent monitoring is essential, especially during treatment, with IV infusions, in patients with renal impairment, or when interacting medications are used. * **Renal function (BUN, creatinine):** To assess the ability to excrete potassium. * **ECG:** Particularly important for IV infusions at higher rates or concentrations, or in patients with cardiac conditions. * **Signs and symptoms of hypokalemia and hyperkalemia.** * **Fluid and electrolyte balance.** ## Clinical Pearls * Oral potassium chloride should always be diluted to minimize gastrointestinal irritation. * Rapid IV administration or high concentrations can cause phlebitis and potentially fatal hyperkalemia. * Continuous ECG monitoring is crucial for IV potassium administration rates exceeding 10-20 mEq/hour. * Dietary intake of potassium can influence the need for supplementation. * Extended-release oral formulations may cause gastrointestinal side effects; consider liquid or microencapsulated forms. *** **Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and clinical guidelines for complete details, including indications, contraindications, warnings, precautions, adverse reactions, and drug interactions, before making any treatment decisions.